Chitosan-coated PLGA nanoparticles for transcutaneous immunization: Skin distribution in lysozyme-sensitized mice

Takeuchi, Issei; Hidaka, Yuna; Oshizaka, Takeshi; Takei, Chihiro; Mori, Kenji; Sugibayashi, Kenji; Makino, Kimiko

doi:10.1016/j.colsurfb.2022.112916

Cited by 3 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In transdermal delivery, it improves the skin permeability of the drug and controls the release of the active drug from the carrier. It has also been reported that PLGA nanoparticles (NPs) pass through the stratum corneum but do not migrate to the dermis or subcutaneous tissue [16,17]. PLGA NPs have been applied in various medical fields as a base material that allows drugs to be absorbed transdermal and used for treatment [18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Development of PSL-Loaded PLGA Nanoparticles for the Treatment of Allergic Contact Dermatitis

Fujisawa,

Sakurai,

Oshizaka

et al. 2024

Colloids and Interfaces

Self Cite

View full text Add to dashboard Cite

Allergic contact dermatitis (ACD) can easily develop once sensitization is established by exposure to small amounts of antigen, and steroids are used for treatment. In this study, we evaluated the therapeutic efficacy of prednisolone (PSL)-loaded poly(DL-lactide-co-glycolide) (PLGA) nanoparticles (NPs) on a mouse model of contact dermatitis (CHS). Nanoparticles were prepared using a poor solvent diffusion method, and particle size distribution and mean particle size were measured using dynamic light scattering. Treatment experiments with PSL-loaded PLGA NPs were performed before and after sensitization with 1-fluoro-2,4-dinitrobenzene (DNFB), and evaluation was performed by quantifying intracutaneous IL-4 and TNF-α levels in a mouse model of CHS using ELISA. When PSL-loaded PLGA NPs were administered before sensitization, IL-4 expression was significantly decreased, and TNF-α tended to decrease in the group treated with PSL-loaded PLGA NPs compared to the non-treated group. When PSL-loaded PLGA NPs were administered after sensitization, IL-4 expression was significantly decreased in the group treated with PSL-loaded PLGA NPs compared to the non-treated group. In both cases, there were no significant differences between the PSL-loaded PLGA NP treatment group and the PSL-containing ointment group. These results suggest that, in the treatment of CHS, PSL-loaded PLGA NPs show a certain therapeutic effect when preadministration.

show abstract